MX347503B - Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada. - Google Patents

Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada.

Info

Publication number
MX347503B
MX347503B MX2013005047A MX2013005047A MX347503B MX 347503 B MX347503 B MX 347503B MX 2013005047 A MX2013005047 A MX 2013005047A MX 2013005047 A MX2013005047 A MX 2013005047A MX 347503 B MX347503 B MX 347503B
Authority
MX
Mexico
Prior art keywords
factor viii
specific activity
increased specific
new variant
antihemophilic factor
Prior art date
Application number
MX2013005047A
Other languages
English (en)
Spanish (es)
Other versions
MX2013005047A (es
Inventor
Kong Lai Chee
Kevin Stafford Roddy
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2013005047A publication Critical patent/MX2013005047A/es
Publication of MX347503B publication Critical patent/MX347503B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2013005047A 2010-11-05 2011-11-04 Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada. MX347503B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41043710P 2010-11-05 2010-11-05
PCT/US2011/059297 WO2012061689A2 (en) 2010-11-05 2011-11-04 A new variant of antihemophilic factor viii having increased specific activity

Publications (2)

Publication Number Publication Date
MX2013005047A MX2013005047A (es) 2013-12-06
MX347503B true MX347503B (es) 2017-04-26

Family

ID=46025129

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013005047A MX347503B (es) 2010-11-05 2011-11-04 Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada.
MX2016015430A MX351220B (es) 2010-11-05 2011-11-04 Una variante nueva del factor viii antihemofilico que tiene actividad especifica incrementada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016015430A MX351220B (es) 2010-11-05 2011-11-04 Una variante nueva del factor viii antihemofilico que tiene actividad especifica incrementada.

Country Status (18)

Country Link
US (2) US9150637B2 (enExample)
EP (1) EP2635297B1 (enExample)
JP (1) JP5922141B2 (enExample)
KR (1) KR101948337B1 (enExample)
CN (1) CN103298483B (enExample)
AU (1) AU2011323236B2 (enExample)
BR (1) BR112013011041B1 (enExample)
CA (1) CA2816575C (enExample)
CO (1) CO6720990A2 (enExample)
DK (1) DK2635297T3 (enExample)
EA (1) EA035447B1 (enExample)
ES (1) ES2721478T3 (enExample)
IL (1) IL226158B (enExample)
MX (2) MX347503B (enExample)
MY (1) MY165089A (enExample)
SG (2) SG10201509149VA (enExample)
WO (1) WO2012061689A2 (enExample)
ZA (1) ZA201303816B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2819123T3 (es) 2015-01-30 2021-04-15 Univ Emory Proteínas del factor VIII que tienen secuencias ancestrales, vectores de expresión, y usos relacionados con ellos
KR102219859B1 (ko) 2016-06-24 2021-02-25 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
MX9203440A (es) 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
JPS6281327A (ja) 1985-10-04 1987-04-14 Green Cross Corp:The 人トロンビン製剤の加熱処理方法
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
JPS6485927A (en) 1987-09-29 1989-03-30 Green Cross Corp Hepatitis b vaccine
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
JPH0626980Y2 (ja) 1987-11-26 1994-07-20 ソニー株式会社 誤消去防止機構
WO1989009784A1 (en) 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5384132A (en) 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5888974A (en) 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
ATE198277T1 (de) 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
WO1994029471A1 (en) * 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
JPH0899999A (ja) 1994-09-30 1996-04-16 Chemo Sero Therapeut Res Inst α１プロテアーゼインヒビターの製造方法
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
WO1997003191A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
PT1754718E (pt) * 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP2002517180A (ja) 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン 増大された発現を示す新規ベクターおよび遺伝子
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP1820516B1 (en) 1999-02-22 2013-07-24 University of Connecticut Novel albumin-free factor VIII formulations
EP1194161B1 (en) 1999-07-13 2005-11-23 Biovitrum Ab Stable factor viii compositions
US6333192B1 (en) 1999-08-09 2001-12-25 North Carolina State University Method of producing an undifferentiated avian cell culture using avian primordial germ cells
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
US7576182B1 (en) 1999-08-31 2009-08-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
PL206105B1 (pl) 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
DE60230456D1 (de) * 2001-10-05 2009-01-29 Expression Therapeutics Llc Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
US20040249134A1 (en) 2001-11-30 2004-12-09 Lollar John S. Factor viii c2 domain variants
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7939634B2 (en) * 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
PL1750733T3 (pl) 2004-05-03 2014-05-30 Univ Emory Sposób podawania świńskiego czynnika krzepnięcia VIII pozbawionego domeny B
DK2371856T3 (en) * 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
WO2009075772A1 (en) 2007-12-06 2009-06-18 Wyeth Crystal structure of human factor viii and uses thereof

Also Published As

Publication number Publication date
MX351220B (es) 2017-10-05
US9150637B2 (en) 2015-10-06
US20130296244A1 (en) 2013-11-07
MX2013005047A (es) 2013-12-06
WO2012061689A2 (en) 2012-05-10
MY165089A (en) 2018-02-28
WO2012061689A3 (en) 2012-10-04
JP2013545459A (ja) 2013-12-26
CA2816575A1 (en) 2012-05-10
US10053500B2 (en) 2018-08-21
EA035447B1 (ru) 2020-06-17
CN103298483B (zh) 2017-04-12
EP2635297A2 (en) 2013-09-11
KR101948337B1 (ko) 2019-02-14
EA201390654A1 (ru) 2014-01-30
SG190136A1 (en) 2013-07-31
SG10201509149VA (en) 2015-12-30
JP5922141B2 (ja) 2016-05-24
CO6720990A2 (es) 2013-07-31
CN103298483A (zh) 2013-09-11
AU2011323236A1 (en) 2013-06-06
EP2635297A4 (en) 2014-06-25
EP2635297B1 (en) 2019-02-27
ZA201303816B (en) 2021-05-26
US20150353625A1 (en) 2015-12-10
IL226158A0 (en) 2013-06-27
DK2635297T3 (da) 2019-05-06
BR112013011041B1 (pt) 2021-05-25
IL226158B (en) 2019-08-29
BR112013011041A2 (pt) 2017-06-06
AU2011323236A8 (en) 2013-07-25
ES2721478T3 (es) 2019-07-31
AU2011323236B2 (en) 2017-03-30
KR20140114266A (ko) 2014-09-26
CA2816575C (en) 2019-06-11

Similar Documents

Publication Publication Date Title
CA144362S (en) Combined dishwashing and scrubbing tool
MY172578A (en) Oral dosing of glp-1 compounds
MX2013001540A (es) Composiciones que comprende un polipeptido que tiene actividad de incremento celulolititico y un compuesto de quinona, y uso de las mismas.
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
ZA201206697B (en) Inverted dome to supply dose
IN2014DN06104A (enExample)
MX2014008774A (es) Sistemas de perfume.
IN2014DN09085A (enExample)
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
MX353299B (es) Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.
BR112014014896A2 (pt) nova combinação
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
MX365707B (es) 6-cloro-3-(fenil-d5)inden-1-ona y su uso.
PH12015500585A1 (en) Modified hyaluronic acid derivatives and use thereof
MX2013002539A (es) Sobrenadante condicionado por leucocitos activados y usos para la cicatrizacion de heridas.
MX2013005047A (es) Una variante nueva del factor viii antihemofilico que tiene actividad especifica incrementada.
CY1117053T1 (el) Συνθεση μελιου με l-αλανυλ-l-γλουταμινη
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
MX354501B (es) Ingrediente perfumante de la familia galbano.
MX2013002485A (es) Fenilacetamidas y fenilpropanamidas sustituidas y su uso.
PH12012502054A1 (en) Dithiinopyridazine-dion derivatives
IN2015DN02647A (enExample)
CA2860159C (en) Peptides targeting receptor activator of nuclear factor-kappa b (rank) and their applications
UA94339C2 (ru) применение корвитина в качестве средства фригопротекторного действия
AU338253S (en) Retail Unloader

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BAXALTA INCORPORATED

FG Grant or registration